120 related articles for article (PubMed ID: 37243926)
1. Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab.
Polano M; Bedon L; Dal Bo M; Sorio R; Bartoletti M; De Mattia E; Cecchin E; Pisano C; Lorusso D; Lissoni AA; De Censi A; Cecere SC; Scollo P; Marchini S; Arenare L; De Giorgi U; Califano D; Biagioli E; Chiodini P; Perrone F; Pignata S; Toffoli G
Clin Pharmacol Ther; 2023 Sep; 114(3):652-663. PubMed ID: 37243926
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial.
He YJ; Winham SJ; Hoskins JM; Glass S; Paul J; Brown R; Motsinger-Reif A; McLeod HL
Pharmacogenomics J; 2016 Jun; 16(3):243-8. PubMed ID: 26194361
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Daniele G; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Zaccarelli E; Nardin M; Bogani G; Distefano M; Greggi S; Piccirillo MC; Fossati R; Giannone G; Arenare L; Gallo C; Perrone F; Pignata S
Int J Gynecol Cancer; 2021 Jun; 31(6):875-882. PubMed ID: 33931498
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
Abaid LN; Lopez KL; Micha JP; Rettenmaier MA; Brown JV; Goldstein BH
Eur J Gynaecol Oncol; 2010; 31(3):308-11. PubMed ID: 21077475
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
6. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.
Daniele G; Lorusso D; Scambia G; Cecere SC; Nicoletto MO; Breda E; Colombo N; Artioli G; Cannella L; Lo Re G; Raspagliesi F; Maltese G; Salutari V; Ferrandina G; Greggi S; Baldoni A; Bergamini A; Piccirillo MC; Tognon G; Floriani I; Signoriello S; Perrone F; Pignata S
Gynecol Oncol; 2017 Feb; 144(2):256-259. PubMed ID: 27993479
[TBL] [Abstract][Full Text] [Related]
7. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R; Arenare L; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Lapresa M; Nardin M; Bogani G; Distefano M; Greggi S; Gargiulo P; Schettino C; Gallo C; Daniele G; Califano D; Perrone F; Pignata S; Piccirillo MC
Int J Gynecol Cancer; 2021 Oct; 31(10):1348-1355. PubMed ID: 34462317
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study.
Landrum LM; Brady WE; Armstrong DK; Moore KN; DiSilvestro PA; O'Malley DM; Tenney ME; Rose PG; Fracasso PM
Gynecol Oncol; 2016 Feb; 140(2):204-9. PubMed ID: 26616225
[TBL] [Abstract][Full Text] [Related]
12. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
13. Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.
Iwasa-Inoue N; Nomura H; Kataoka F; Chiyoda T; Yoshihama T; Nanki Y; Sakai K; Kobayashi Y; Yamagami W; Morisada T; Hirasawa A; Aoki D
Int J Clin Oncol; 2022 Feb; 27(2):441-447. PubMed ID: 34648082
[TBL] [Abstract][Full Text] [Related]
14. Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gillen J; Miller A; Bell-McGuinn KM; Schilder RJ; Walker JL; Mathews CA; Duska LR; Guntupalli SR; O'Cearbhaill R; Hays J; Hagemann AR; Gray HJ; Gordon SW; Armstrong DK; Chen A; Fracasso PM; Aghajanian C; Moore KN
Gynecol Oncol; 2021 May; 161(2):512-515. PubMed ID: 33610319
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Abe M; Shoji T; Chiba Y; Takatori E; Kaido Y; Nagasawa T; Kagabu M; Takahashi F; Aida T; Baba T
Anticancer Res; 2023 Mar; 43(3):1265-1272. PubMed ID: 36854492
[TBL] [Abstract][Full Text] [Related]
16. Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Svedberg A; Björn N; Sigurgeirsson B; Pradhananga S; Brandén E; Koyi H; Lewensohn R; De Petris L; Apellániz-Ruiz M; Rodríguez-Antona C; Lundeberg J; Gréen H
Lung Cancer; 2020 Sep; 147():106-114. PubMed ID: 32683206
[TBL] [Abstract][Full Text] [Related]
17. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Nasu H; Nishio S; Park J; Yoshimitsu T; Matsukuma K; Tasaki K; Katsuda T; Terada A; Tsuda N; Ushijima K
Int J Clin Oncol; 2022 Apr; 27(4):790-801. PubMed ID: 34985551
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
Furlanetto J; Möbus V; Schneeweiss A; Rhiem K; Tesch H; Blohmer JU; Lübbe K; Untch M; Salat C; Huober J; Klare P; Schmutzler R; Couch FJ; Lederer B; Gerber B; Zahm DM; Bauerfeind I; Nekljudova V; Hanusch C; Jackisch C; Link T; Hahnen E; Loibl S; Fasching PA
Eur J Cancer; 2021 Mar; 145():44-52. PubMed ID: 33423006
[TBL] [Abstract][Full Text] [Related]
20. Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: active combination with low incidence of peripheral neuropathy.
Vorobiof DA; Rapoport BL; Chasen MR; Cohen GL; Mahomed R; Karime M
Int J Gynecol Cancer; 2003; 13(3):287-91. PubMed ID: 12801257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
